Enzyme Replacement Therapy Market, By Enzyme Type (Agalsidase Beta, Velaglucerase Alfa, Imiglucerase, Taliglucerase, Alglucosidase, Alfa, Laronidase, Idursulfase, Galsulfase, Pegademase, and Others), By Indication (Fabry Disease, Gaucher Disease, Pompe Disease, Scheie Syndrome, Hunter Disease, Maroteaux-Lamy Syndrome, and Others), By End User ( Hospitals, Clinics, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2030

The global enzyme replacement therapy market size accounted for US$ 8.28 billion in 2020 and is estimated to be US$ 16.94 billion by 2030 and is anticipated to register a CAGR of 7.50%.

Enzyme replacement therapy involves intravenous IV infusions to correct the underlying enzyme deficiency that may cause different type diseases, which include gaucher disease, fabry disease, pompe disease, hunter disease, pompe disease, scheie syndrome, maroteauxlamy syndrome and others.  Enzyme replacement therapy involves intravenous treatment to correct the underlying enzyme deficiency of human body. Certain type of enzyme deficiencies may cause different types of diseases which include gaucher disease, pompe disease, fabry disease, hunter disease, scheie syndrome, maroteauxlamy syndrome, and others. This treatment principle has been taken into consideration for other LSDs as enzyme replacement therapy has been successfully introduced for patients with Gaucher disease type 1. Nevertheless, repeating this remarkable success in the mucopolysaccharidoses and Fabry or Pompe disease has proven to be impossible. Enzyme replacement therapy has also been used to treat patients with severe combined immunodeficiency resulting from an adenosine deaminase deficiency.

Increasing prevalence of lysosomal storage

Increasing prevalence of lysosomal storage disease which particularly require enzyme replacement therapy for its treatment is major factor driving the growth of global enzyme replacement therapy market. For instance, according to data published by National Gauchar Foundation, gaucher disease type 1 (pronounced go-SHAY) is the most prevalent form of the disease in western countries, making up about 95 percent of cases there. Also, gaucher disease type 1 is also the most common jewish genetic disorder. It is likely that about 1 in 450 people of Ashkenazi jewish lineage have certain form of the disease. In addition, increasing number of approvals from regulatory bodies for novel enzyme replacement therapies is also one of the key factor fueling growth of the global enzyme replacements therapy market. For instance, in 2017, Food and Drug Administration (FDA) approved, Ultragenyx Pharmaceutical’s Mepsevii (vestronidase alfa), its enzyme replacement therapy for children and adults with mucopolysaccharidosis VII (MPS VII). However, lack of awareness about enzyme replacement therapy in lower economic countries is expected to hamper growth of the global enzyme therapy market. Major players are looking forward and invest in research activities for developing advanced enzyme replacement therapies, which is expected to boost demand for enzyme replacement therapy over the forecast period.

Furthermore, the increasing collaborations amongst key companies to fast-track the development of enzymes for replacement is expected to boost growth of the enzyme replacement therapy market size. Additionally, the approval for new enzyme replacement is also expected to propel the enzyme replacement therapy market. 

However, the high cost of enzyme replacement therapy and stringent reimbursement scenario, as the enzyme replacement therapy is been mostly used for rare diseases hampers the growth of enzyme replacement therapy market. 

Moreover, major investments by key players for research and development new enzyme replacement therapies, in turn being benefitted from orphan drug status and fast-track approval.

On the basis of enzyme type, the global enzyme replacement therapy has been segmented into Agalsidase Beta, Velaglucerase Alfa, Imiglucerase, Taliglucerase, Alglucosidase Alfa, Laronidase, Idursulfase, Galsulfase, Pegademase, and Others.

On the basis of indication the global enzyme replacement therapy market is segmented into Fabry Disease, Gaucher Disease, Pompe Disease, Scheie Syndrome, Hunter Disease, Maroteaux-Lamy Syndrome, and Others

On the basis of end user, the global enzyme replacement therapy market is segmented into Hospitals, Clinics and Home care setting.

On the basis of region, the target market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is expected to account major market share as compared to that of other regions.

Regional Analysis:

For detailed understanding of market dynamics, the global epigenetics market is analyzed across key regions viz North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the global market. In 2020, North America is expected to register significant growth in the global enzyme replacement therapy market over the forecast period. This is owing to increasing adoption of novel therapies as well as increasing prevalence of enzyme deficiency in the countries of the region. Further, favorable reimbursement policies, drug availability, and advanced healthcare infrastructure is expected to drive the market growth in North America and Europe. Asia Pacific market is expected to be the fastest growing market in terms of revenue over the forecast period. This is attributed to low cost of enzyme replacement therapies and rising awareness about enzyme replacement therapy in the countries of the region.

Report Scope:

Enzyme Replacement Therapy Market, By Enzyme Type:

• Agalsidase beta
• Velaglucerase alfa
• Imiglucerase
• Taliglucerase
• Alglucosidase alfa
• Laronidase
• Idursulfase
• Galsulfase
• Pegademase
• Others

Enzyme Replacement Therapy Market, By Indication

• Fabry disease
• Gaucher disease
• Pompe disease
• Scheie syndrome
• Hunter disease
• Maroteaux-lamy syndrome
• Others

Enzyme Replacement Therapy Market, By End-User

• Hospitals
• Clinics
• Home care setting

Enzyme Replacement Therapy Market, By Region:

• North America
  • Middle East & Africa
    • Middle East & Africa Enzyme Replacement Therapy Market, By Enzyme Type
    • Middle East & Africa Enzyme Replacement Therapy Market, By Indication
    • Middle East & Africa Enzyme Replacement Therapy Market, By End-User
    • Middle East & Africa Enzyme Replacement Therapy Market, By Country
      • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • Latin America Enzyme Replacement Therapy Market, By Enzyme Type
    • Latin America Enzyme Replacement Therapy Market, By Indication
    • Latin America Enzyme Replacement Therapy Market, By End-User
    • Latin America Enzyme Replacement Therapy Market, By Country
      • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • Asia Pacific Enzyme Replacement Therapy Market, By Enzyme Type
    • Asia Pacific Enzyme Replacement Therapy Market, By Indication
    • Asia Pacific Enzyme Replacement Therapy Market, By End-User
    • Asia Pacific Enzyme Replacement Therapy Market, By Country
      • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific                                                                                                                                                                                  
  • Europe
    • Europe Enzyme Replacement Therapy Market, By Enzyme Type
    • Europe Enzyme Replacement Therapy Market, By Indication
    • Europe Enzyme Replacement Therapy Market, By End-User
    • Europe Enzyme Replacement Therapy Market, By Country
      • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • North America Enzyme Replacement Therapy Market, By Enzyme Type
  • North America Enzyme Replacement Therapy Market, By Indication
  • North America Enzyme Replacement Therapy Market, By End-User
  • North America Enzyme Replacement Therapy Market, By Country
    • U.S.
    • Canada

 Some of the prominent players operating in the global enzyme replacement therapy market include Shire plc, Amicus Therapeutics Inc., Genzyme Corporation, Pfizer Inc., BioMarin Pharmaceutical, Inc., Sigma-Tau Pharmaceuticals, Inc., NanoMedSyn, Essential Pharmaceuticals Limited, Merck KGa, and AbbVie Inc. Advancements in the product as well as in manufacturing process, product launches, and strategic partnerships are some trends witnessed in the global enzyme replacement therapy market. For instance, in 2018, Shire plc, the global biotechnology leader in rare diseases and NanoMedSyn, a biotechnology company dedicated to innovation in enzyme replacement therapy (ERT), announced that the companies have entered into a preclinical research partnership to evaluate a potential ERT using NanoMedSyn's proprietary synthetic derivatives named AMFA.

Market Taxonomy:

This report segments the global enzyme replacement therapy market on the basis of enzyme type, indication, end user, and region. On the basis of enzyme type, the target market is classified into agalsidase beta, velaglucerase alfa, imiglucerase, taliglucerase, alglucosidase alfa, laronidase, idursulfase, galsulfase, pegademase, and others. Based on indication, the global market is categorized into fabry disease, gaucher disease, pompe disease, scheie syndrome, hunter disease, maroteaux-lamy syndrome, and others. On the basis of end user, the target market is bifurcated into hospitals, clinics, and others.

Key features of the study:

Prophecy Market Insights provides detailed analysis on enzyme replacement therapy market in our report- Global Enzyme Replacement Therapy Market by enzyme type, indication, end user, and region. The report provides market size (US$ Mn) and compounded annual growth rate (%) for the forecast period: 2019 – 2029, considering 2018 as the actual year. The report also contains in-depth analysis about market drivers, restraints, opportunities, new product launches, product approval, ongoing trends, customers demand, and regional outlook. The report delivers competitive analysis about leading players in the global enzyme replacement therapy market based on various parameters such as company overview, product portfolio, regional presence, financial performance, distribution strategies, key developments, marketing strategies, and future plans. The analysis from the report would acquaint the marketers and management authorities of companies to make the appropriate decision with respect to their future product launch, ongoing trends, market expansion, and marketing tactics used overall the globe. Various strategy matrices include in the report are PEST analysis, PORTER’s five forces analysis, and opportunity map analysis to analyze the enzyme replacement therapy market.

• • • Shire plc
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • Amicus Therapeutics Inc
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • Genzyme Corporation
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • Pfizer Inc
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • BioMarin Pharmaceutical, Inc.
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • Sigma-Tau Pharmaceuticals, Inc.
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • Essential Pharmaceuticals Limited
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • Merck KGa
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • NanoMedSyn
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • AbbVie Inc
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance